NCT01129297Recruiting
A Biological Atlas of Severe Obesity (Biological Tissue Collection)
Influence of the Glycemic and Ponderal Status on Tissues Gene Expression (Biological Tissue Collection)
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
Type 2 diabetes and obesity are both multifactorial diseases resulting from gene-environment interactions. However, this interaction, as well as the specific effect of each polymorphism, remains poorly understood. We now proposed a prospective cohort study to improve our understanding of the influence of phenotypic characteristics on gene expression in tissues involved in glucose and/or lipid metabolism by collecting different biological samples.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20000 (estimated)
- First submitted
- 4 May 2010
- Start date
- 13 Jun 2006
- Primary completion date
- Jun 2027
- Lead sponsor
- University Hospital, Lille
- Diseases
- Obesity
- NCT number
- NCT01129297
What you commit to
- Study type: Observational
- Planned participants: 20000
- From 13 Jun 2006 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- unable to receive clear information
- refusal to sign the consent form
- pathology associated judged by the surgeon, may increase the risk of adverse events related to sampling tissue
Who the study is looking for
- Age between 18 and 65 years
- Indication of abdominal surgery requiring a laparotomy or laparoscopy for bariatric surgery, cholecystectomy, or parietal surgical
- Phenotype corresponding to one of the following four cases :
- Body Mass Index ≥ 35 kg/m2 and diabetes defined by a fasting blood glucose ≥ 7 mmol/l and/or ≥ to 11.1 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)
- Body Mass Index ≥ 35 kg/m2 with intolerance glucose defined by a fasting blood glucose\> 6 mmol/L and \<7 mmol/l and/or\> 7.8 mmol/l and \<11.1 mmol/l , 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)
- Body Mass Index ≥ 35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)
- Body Mass Index \<27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)
- 5)27 \<Body Mass Index \<35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lille University Hospital Coordinator of this site? Confirm its status | Lille | France | Recruiting |
Related publications
- Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients.BMC Med Genomics · 2019 · PMID 31159817
This page is information, not medical advice. Discuss any trial with your doctor.